Glycolipid C34
Glycolipid C34, α-GalCer (HY-102022) analog, is a CD1d-binding glycolipid antinfection agent. Glycolipid C34 mediates invariant natural killer T cell activation and increases the secretion of IFN-γ and IL-4. Glycolipid C34 promotes clearance of bacterial infections in murine models and enhances protective immunity against viral infections. Glycolipid C34 can be used for the research of bacterial infection, viral infection.
For research use only. We do not sell to patients.
- CAS No.: 1204401-08-0
- Formula: C47H76FNO10
- Molecular Weight:834.11
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
CD1d |
IL-4 |
Glycolipid C34 (150 μg/kg; i.p.; single dose; 3 hours post-infection) significantly reduces bacterial burden in S. aureus Xen29 thigh-infected BALB/c mice[1].
Glycolipid C34 (150 μg/kg; i.p.; single dose; 0-6 h post-infection) significantly reduces bacterial burden in S. aureus Xen29 thigh-infected BALB/c mice at 0 h, with delayed administration (6 hours post-infection) showing reduced efficacy[1].
Glycolipid C34 (1 μg; i.p.; two doses; 1 day pre- and 1 day post-challenge) increases survival of JEV- and WSN-infected C57BL/6 mice, with protection dependent on intact innate and adaptive immune components[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, 6 to 8 weeks old; Sphingomonas capsulata infection model)[1]
-
Dosage:50 μg/kg
-
Administration:i.p.; single dose; 3 hours post-infection
-
Result:Significantly reduced liver bacterial CFU counts compared to vehicle control (P < 0.01), with mean CFU counts lower than those seen with α-GalCer treatment.
-
Animal Model:BALB/c (female; Staphylococcus aureus Xen29 deep thigh wound infection model)[1]
-
Dosage:150 μg/kg
-
Administration:i.p.; single dose; 0, 3, 6 hours post-infection
-
Result:Significantly reduced relative luminescence units (a marker of bacterial burden) compared to vehicle control (P < 0.05), with a greater degree of bacterial clearance than seen with α-GalCer treatment.
-
Animal Model:C57BL/6 (7 weeks old; Japanese encephalitis virus RP-9 strain and influenza virus WSN infection model)[1]
-
Dosage:1 μg
-
Administration:i.p.; two doses; 1 day pre-challenge and 1 day post-challenge
-
Result:Significantly prolonged survival compared to vehicle control.
Chemical Information
-
CAS No. 1204401-08-0
-
Molecular Weight 834.11
-
Formula C47H76FNO10
-
SMILES
CCCCCCCCCCCCCC[C@H]([C@H]([C@@H](NC(CCCCCCCCCCC1=CC=C(C=C1)OC2=CC=C(C=C2)F)=O)CO[C@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3O)O)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Glycolipid C34 Related Classifications
Cat. No.: HY-186103
Powered by Bioz
- Glycolipid C34
- 1204401-08-0
- Glycolipid C 34
- Glycolipid C-34
- CD1
- IFNAR
- Interleukin Related
- Bacterial
- Influenza Virus
- Stat-1
- Sphingomonas capsulata
- murine models
- Japanese encephalitis virus
- CD1d
- CD8α chain
- C57BL/6 mice
- T-helper-cell 1 cytokine response
- immunoglobulin μ chain
- invariant natural killer T cell
- Inhibitor
- inhibitor
- inhibit